Shares of C.R. Bard Inc. (NYSE:BCR) reached a new 52-week high during mid-day trading on Monday . The company traded as high as $239.43 and last traded at $237.89, with a volume of 160,484 shares changing hands. The stock had previously closed at $239.00.

BCR has been the subject of a number of research analyst reports. Zacks Investment Research lowered C.R. Bard from a “buy” rating to a “hold” rating in a report on Tuesday, April 12th. Leerink Swann increased their target price on C.R. Bard from $196.00 to $205.00 and gave the company a “market perform” rating in a report on Wednesday, March 30th. Barclays PLC increased their target price on C.R. Bard from $212.00 to $224.00 and gave the company an “equal weight” rating in a report on Tuesday, May 24th. Needham & Company LLC restated a “hold” rating on shares of C.R. Bard in a report on Tuesday, May 24th. Finally, Bank of America Corp. reiterated a “buy” rating on shares of C.R. Bard in a report on Monday, May 23rd. Ten analysts have rated the stock with a hold rating and five have given a buy rating to the stock. C.R. Bard has a consensus rating of “Hold” and a consensus target price of $220.13.

The stock’s 50 day moving average is $226.31 and its 200 day moving average is $203.83. The firm has a market cap of $17.40 billion and a P/E ratio of 160.42.

C.R. Bard (NYSE:BCR) last announced its quarterly earnings results on Wednesday, April 27th. The company reported $2.34 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.17 by $0.17. During the same period last year, the firm earned $2.10 EPS. The firm earned $873.50 million during the quarter, compared to analyst estimates of $845.77 million. C.R. Bard’s quarterly revenue was up 6.6% on a year-over-year basis. On average, analysts predict that C.R. Bard Inc. will post $10.15 EPS for the current year.

The company also recently declared a quarterly dividend, which will be paid on Friday, July 29th. Stockholders of record on Monday, July 18th will be issued a $0.26 dividend. This represents a $1.04 annualized dividend and a dividend yield of 0.44%. This is a positive change from C.R. Bard’s previous quarterly dividend of $0.24. The ex-dividend date of this dividend is Thursday, July 14th.

In other news, CFO Christopher S. Holland sold 3,970 shares of the business’s stock in a transaction on Friday, May 27th. The shares were sold at an average price of $219.89, for a total value of $872,963.30. Following the completion of the transaction, the chief financial officer now owns 31,306 shares of the company’s stock, valued at approximately $6,883,876.34. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, VP Sharon M. Luboff sold 10,000 shares of the company’s stock in a transaction on Wednesday, April 27th. The stock was sold at an average price of $210.00, for a total transaction of $2,100,000.00. Following the completion of the transaction, the vice president now directly owns 33,706 shares of the company’s stock, valued at $7,078,260. The disclosure for this sale can be found here.

Other institutional investors recently made changes to their positions in the company. Daiwa Securities Group Inc. raised its position in shares of C.R. Bard by 33.3% in the fourth quarter. Daiwa Securities Group Inc. now owns 6,000 shares of the company’s stock worth $1,137,000 after buying an additional 1,500 shares during the last quarter. Herndon Capital Management LLC bought a new position in shares of C.R. Bard during the fourth quarter worth $1,428,000. SECOR Capital Advisors LP raised its position in shares of C.R. Bard by 118.3% in the fourth quarter. SECOR Capital Advisors LP now owns 7,720 shares of the company’s stock worth $1,462,000 after buying an additional 4,184 shares during the last quarter. Deere & Co. raised its position in shares of C.R. Bard by 1.3% in the fourth quarter. Deere & Co. now owns 9,227 shares of the company’s stock worth $1,748,000 after buying an additional 118 shares during the last quarter. Finally, Trexquant Investment LP bought a new position in shares of C.R. Bard during the fourth quarter worth $1,862,000.

C. R. Bard, Inc (Bard) and its subsidiaries are engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company sells its products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.